Literature DB >> 15599214

The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center [corrected].

Mark V Galan1, Jeffrey A Potts, Ann L Silverman, Stuart C Gordon.   

Abstract

BACKGROUND/GOALS: There are limited data regarding the frequency and proportionality of drug-induced hepatotoxicity in the United States. We sought to determine the scope of nonfulminant drug-induced hepatitis as seen in a community-based hepatology referral service. STUDY: From a population of 4,039 outpatients referred for evaluation of acute (n = 96) and chronic (n = 3,943) liver disease over a 10-year period, we reviewed the records of those patients diagnosed with acute bona fide drug-induced hepatitis.
RESULTS: Thirty-two patients presented with self-limited acute drug-induced hepatitis, representing 0.8% of all hepatology patients and 33% of those patients presenting with acute liver injury. Antibiotics (amoxicillin/clavulanic acid, minocycline, nitrofurantoin, an investigational ketolide antibiotic, trimethoprim-sulfamethoxazole, and trovafloxacin) were the class of drugs most frequently implicated (14 of 32; 44%), while amiodarone was the single agent most commonly associated with liver injury (7 of 32; 22%). The mean age of affected patients was 52.2 years, and we found a male predominance (18 of 32; 56%). The mean time to biochemical resolution after discontinuation of the offending agent was 14.1 weeks.
CONCLUSIONS: Drug-induced hepatitis is an uncommon entity in clinical hepatology but does represent a significant proportion of acute self-limited liver disease in the United States. Antibiotics and amiodarone were the most common drug culprits in our population. Time to resolution following the discontinuation of the offending agent may be protracted. Prospective studies are needed to further assess the burden of drug-induced liver injury.

Entities:  

Mesh:

Year:  2005        PMID: 15599214

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  21 in total

1.  Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset.

Authors:  Robert J Fontana; Paul H Hayashi; Jiezhun Gu; K Rajender Reddy; Huiman Barnhart; Paul B Watkins; Jose Serrano; William M Lee; Naga Chalasani; Andrew Stolz; Timothy Davern; Jayant A Talwakar
Journal:  Gastroenterology       Date:  2014-03-27       Impact factor: 22.682

Review 2.  Important elements for the diagnosis of drug-induced liver injury.

Authors:  Vijay K Agarwal; John G McHutchison; Jay H Hoofnagle
Journal:  Clin Gastroenterol Hepatol       Date:  2010-02-17       Impact factor: 11.382

3.  Liver and pancreatic injury induced by antituberculous therapy.

Authors:  M Markov; K Patel; A Raeesy; A Bant; D H Van Thiel; A Nadir
Journal:  Dig Dis Sci       Date:  2007-02-15       Impact factor: 3.199

Review 4.  Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting.

Authors:  Sarah Tischer; Robert J Fontana
Journal:  J Hepatol       Date:  2013-11-23       Impact factor: 25.083

Review 5.  Drug-induced liver injury: review article.

Authors:  Wissam Bleibel; Stephen Kim; Karl D'Silva; Eric R Lemmer
Journal:  Dig Dis Sci       Date:  2007-03-16       Impact factor: 3.199

Review 6.  Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives.

Authors:  Robert J Fontana
Journal:  Gastroenterology       Date:  2013-12-31       Impact factor: 22.682

7.  Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop.

Authors:  Robert J Fontana; Leonard B Seeff; Raúl J Andrade; Einar Björnsson; Christopher P Day; Jose Serrano; Jay H Hoofnagle
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

Review 8.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Drug-induced liver graft toxicity caused by cytochrome P450 poor metabolism.

Authors:  László Kóbori; Krisztina Kõhalmy; Pálma Porrogi; Enikõ Sárváry; Zsuzsa Gerlei; János Fazakas; Péter Nagy; Jenõ Járay; Katalin Monostory
Journal:  Br J Clin Pharmacol       Date:  2007-12-07       Impact factor: 4.335

10.  Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct.

Authors:  Robert J Fontana; Paul B Watkins; Herbert L Bonkovsky; Naga Chalasani; Timothy Davern; Jose Serrano; James Rochon
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.